A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Clinical trial NCT06653153 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06653153
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-24
- Primary completion
- 2029-04-01
- Enrollment
- 1400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.